Jeff Jonas, Kenai Therapeutics chairman
'Sweet spot' of CNS cell therapy: Kenai emerges with $82M for Parkinson's study
One of the first drugs that Jeff Jonas filed for approval was a Parkinson’s disease treatment. Now, a little over a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
